- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Ira Klein on Pharmaceutical Interest in Alternative Payment Models
Pharmaceutical companies would like to see value-based contracts that are multi-year and over large populations, said Ira Klein, MD, MBA, FACP, senior director of healthcare quality strategy for the Strategic Customer Group at Janssen Pharmaceuticals.
Pharmaceutical companies would like to see value-based contracts that are multi-year and over large populations, said Ira Klein, MD, MBA, FACP, senior director of healthcare quality strategy for the Strategic Customer Group at Janssen Pharmaceuticals.
Transcript (slightly moified)
What are pharmaceutical companies interested in with respect to alternative payment models?
I think that anything that really helps in unlocking the true value of a product over time is what the pharmaceutical industry is interested in. Now, if you think about the research and development time cycle, and the amount of failure of potential drugs to make it to market, it’s really a very long ramp up for the few products that actually make it. So, when you think about measuring a value in value-based contracts, it’s probably difficult to actually capture the real value in a 12-month contract, because drugs by meliorating disease, meliorating suffering, tend to have their real value explained over a number of years. Actuarially, while this may become more difficult, I think value-based contracts, if they can be multi-year and over large populations, those are the things we would like to see in the contract.
We’d also like to be able to measure some of the factors that are not traditionally measured, but are very important to patients, such as their quality of life, their outcomes, and what it means for them to be able to care for others, maintain employment, and participate in meaningful activities that they otherwise wouldn’t be able to participate in.
Additionally, I just want to say that as we move into a more aggregated system, where the delivery side has become more group-oriented in ACOs and IDNs, we think that the ability to manage these value-based contracts will become easier because these aggregated delivery systems will be able to present us with that large set of holistic data that I referred to that we will need to actually show the real value of the products in the marketplace for real patients.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
